# US 2021/0275610 A1 · Microbiome markers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275610 A1
- Document ID: US20210275610A1
- Status: Published application
- Kind: A1
- Application number: 17/328,849
- Filed: 2021-05-24
- Published: 2021-09-09
- Earliest claimed: 2018-09-13
- Assignees: Gnubiotics Sciences SA
- Applicants: Gnubiotics Sciences SA
- Inventors: Adeyemi Adesokan
- Web page: https://patentgrep.com/patent/US20210275610A1

## CPC

- C12Q 1/689: for bacteria
- A23K 10/18: of live microorganisms
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 38/1735: {Mucins, e.g. human intestinal mucin}
- A61P 3/04: Anorexiants; Antiobesity agents
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- A61K 2035/115: {Probiotics}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Bacterial species acting as biomarkers for obesity in domesticated cats and/or dogs are disclosed herein. Also disclosed are methods for diagnosing and/or treating cats and/or dogs having obesity or a predisposition to obesity as well as methods of screening for agents to treat or prevent obesity.

## Claims

### Claim 1

A method of selecting and treating a domesticated dog for obesity or a predisposition to obesity comprising the steps of:
a. selecting a domesticated dog on the basis of it having a gut population of one or more bacterial species selected from Eubacterium tenue and Clostridium hiranonis at a level below a pre-determined threshold for the selected bacterial species; and
b. treating the selected dog for obesity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment comprises orally administering to the dog an agent that selectively increases the gut population of one or more bacterial species selected from Eubacterium tenue and Clostridium hiranonis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the treatment comprises orally administering to the dog an agent comprising mucins.

### Claim 4 (depends on 3)

The method of claim 3, wherein the mucins comprise porcine mucins.

### Claim 5 (depends on 4)

The method of claim 4, wherein the porcine mucins are obtained from porcine gastrointestinal tract.

### Claim 6 (depends on 5)

The method of claim 5, wherein the agent comprises less than 1% free glycans.

### Claim 7 (depends on 2)

The method of claim 2, wherein the treatment comprises orally administering to the dog one or more bacterial species selected from Eubacterium tenue and Clostridium hiranonis.

### Claim 8

A method of processing a sample from a domesticated dog suspected of being obese or having a predisposition to obesity comprising the steps of:
a. obtaining a biological sample from a domesticated dog; and
b. measuring the expression of one or more bacterial species, wherein the bacterial species is selected from the group consisting of Eubacterium tenue and Clostridium hiranonis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the expression of both Eubacterium tenue and Clostridium hiranonis are measured.

### Claim 10 (depends on 8)

The method of claim 8, wherein the biological sample is a fecal sample.

### Claim 11

A method of screening one or more test agents to identify candidate agents for treating, reducing the likelihood, or preventing obesity in a dog, comprising:
a) providing a bacterial culture comprising one or more bacterial species selected from Eubacterium tenue and Clostridium hiranonis,
b) contacting the culture with the one or more test agents,
c) determining the level of the one or more bacterial species in the contacted culture, and
d) identifying the one or more test agents as candidate agents if the contacted culture has a decreased level of the one or more bacterial species as compared to a control.

### Claim 12 (depends on 11)

The method of claim 11, wherein the culture further comprises mucus.

### Claim 13 (depends on 11)

The method of claim 11, wherein the culture has been obtained with a dog fecal sample inoculum.
